Rigel Pharmaceuticals, Inc. (RIGL)
Rigel Pharmaceuticals, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Rigel Pharmaceuticals, Inc. (RIGL) is a Biotechnology company based in US with a market capitalization of $727.3M. Revenue grew 64.2% year-over-year and the company generated $75.7M in free cash flow. This page tracks RIGL's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 162 employees · IPO Nov 29, 2000
Valuation
Valuation & price
$29.01as of May 17, 2026· -43.1% vs 52w high
1.5
P/E ratio
Latest-FY diluted EPS
1.86
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$727.3M
Market cap
64.2%
Revenue growth (YoY)
93.3%
Gross margin
$75.7M
Free cash flow (USD)
-$101.7M
Net debt
Net cash position
2.3%
Share dilution
3/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
2
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 5, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- 8-K eventJul 1, 2026Filing
Executive Appointment
- Insider sellJun 24, 2026Filing
Insider Sell $88K · 10b5-1 PlanAli-Jackson Kamil · Director · $87.5K
- 8-K eventJun 17, 2026Filing
Acquisition Completed
- Insider sellMay 28, 2026Filing
Insider Sell $73K · 10b5-1 PlanAli-Jackson Kamil · Director · $72.9K
- 8-K eventMay 20, 2026Filing
Stockholder Meeting Results
- 8-K eventMay 12, 2026Filing
License Agreement Signed
- Quarterly reportMay 5, 2026Filing
10-Q Filed
- 8-K eventMay 5, 2026Filing
Earnings Release
- 8-K eventApr 21, 2026Filing
Termination of Agreement
Questions
Frequently asked questions
What is Rigel Pharmaceuticals, Inc.'s market cap?
Rigel Pharmaceuticals, Inc. (RIGL) has a market capitalization of $727.3M.
What is RIGL's P/E ratio?
RIGL trades at a price-to-earnings ratio of 1.5, based on its latest fiscal-year diluted earnings per share and the most recent cached price.
What is RIGL's price-to-book (P/B) ratio?
RIGL trades at 1.86 times book value per share.
Are insiders buying RIGL stock?
SEC Form 4 filings show no open-market insider buys at Rigel Pharmaceuticals, Inc. in the last 90 days (2 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.